RxDoctor Payments Data

Chukwunomnso Dennar, MD

Internal Medicine · New Orleans, LANPI 1326153131

Payments from drug & device makers

$323in general payments, 2019–2025

Across 12 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$125
  • Boehringer Ingelheim$67
  • Radius Health, Inc.$30
  • Currax Pharmaceuticals LLC$30
  • Lilly USA, LLC$23
  • AbbVie$21
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$323 in reported general payments places this provider in the 45th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,541
Medicare patients
29
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$76,003
JanuviaSitagliptin Phosphate51$56,469
CreonLipase/Protease/Amylase14$54,729
JardianceEmpagliflozin63$49,824
LinzessLinaclotide54$39,739
InvokanaCanagliflozin28$32,412
EliquisApixaban32$22,510
MounjaroTirzepatide18$21,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,139
Atrovent HfaIpratropium Bromide19$8,633
Spiriva HandihalerTiotropium Bromide12$6,291
SymbicortBudesonide/Formoterol Fumarate15$3,362
Novolog FlexpenInsulin Aspart14$2,411
Lidocaine25$2,016
Albuterol Sulfate HfaAlbuterol Sulfate95$1,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$21$94,46868 claims
Boehringer IngelheimJardiance$67$49,82463 claims
Lilly USA, LLCMounjaro$23$21,69818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →